Literature DB >> 33010159

PROTAC-DB: an online database of PROTACs.

Gaoqi Weng1,2, Chao Shen1, Dongsheng Cao3, Junbo Gao1, Xiaowu Dong1, Qiaojun He1, Bo Yang1, Dan Li1, Jian Wu4, Tingjun Hou1,2.   

Abstract

Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted proteins by the ubiquitin-proteasome system, have emerged as a novel therapeutic technology with potential advantages over traditional inhibition strategies. In the past few years, this technology has achieved substantial progress and two PROTACs have been advanced into phase I clinical trials. However, this technology is still maturing and the design of PROTACs remains a great challenge. In order to promote the rational design of PROTACs, we present PROTAC-DB, a web-based open-access database that integrates structural information and experimental data of PROTACs. Currently, PROTAC-DB consists of 1662 PROTACs, 202 warheads (small molecules that target the proteins of interest), 65 E3 ligands (small molecules capable of recruiting E3 ligases) and 806 linkers, as well as their chemical structures, biological activities, and physicochemical properties. Except the biological activities of warheads and E3 ligands, PROTAC-DB also provides the degradation capacities, binding affinities and cellular activities for PROTACs. PROTAC-DB can be queried with two general searching approaches: text-based (target name, compound name or ID) and structure-based. In addition, for the convenience of users, a filtering tool for the searching results based on the physicochemical properties of compounds is also offered. PROTAC-DB is freely accessible at http://cadd.zju.edu.cn/protacdb/.
© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Year:  2021        PMID: 33010159      PMCID: PMC7778940          DOI: 10.1093/nar/gkaa807

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  26 in total

1.  PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.

Authors:  Kanak Raina; Jing Lu; Yimin Qian; Martha Altieri; Deborah Gordon; Ann Marie K Rossi; Jing Wang; Xin Chen; Hanqing Dong; Kam Siu; James D Winkler; Andrew P Crew; Craig M Crews; Kevin G Coleman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

2.  Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.

Authors:  Yangbing Li; Jiuling Yang; Angelo Aguilar; Donna McEachern; Sally Przybranowski; Liu Liu; Chao-Yie Yang; Mi Wang; Xin Han; Shaomeng Wang
Journal:  J Med Chem       Date:  2018-12-10       Impact factor: 7.446

3.  Targeted protein degradation: expanding the toolbox.

Authors:  Matthieu Schapira; Matthew F Calabrese; Alex N Bullock; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2019-10-30       Impact factor: 84.694

Review 4.  Development of targeted protein degradation therapeutics.

Authors:  Philip P Chamberlain; Lawrence G Hamann
Journal:  Nat Chem Biol       Date:  2019-09-16       Impact factor: 15.040

5.  Targeted degraders clear first safety hurdles.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2020-07       Impact factor: 84.694

Review 6.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

7.  A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.

Authors:  Longchuan Bai; Haibin Zhou; Renqi Xu; Yujun Zhao; Krishnapriya Chinnaswamy; Donna McEachern; Jianyong Chen; Chao-Yie Yang; Zhaomin Liu; Mi Wang; Liu Liu; Hui Jiang; Bo Wen; Praveen Kumar; Jennifer L Meagher; Duxin Sun; Jeanne A Stuckey; Shaomeng Wang
Journal:  Cancer Cell       Date:  2019-11-11       Impact factor: 31.743

8.  Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics.

Authors:  Ashley R Schneekloth; Mathieu Pucheault; Hyun Seop Tae; Craig M Crews
Journal:  Bioorg Med Chem Lett       Date:  2008-07-31       Impact factor: 2.823

9.  Plasticity in binding confers selectivity in ligand-induced protein degradation.

Authors:  Radosław P Nowak; Stephen L DeAngelo; Dennis Buckley; Zhixiang He; Katherine A Donovan; Jian An; Nozhat Safaee; Mark P Jedrychowski; Charles M Ponthier; Mette Ishoey; Tinghu Zhang; Joseph D Mancias; Nathanael S Gray; James E Bradner; Eric S Fischer
Journal:  Nat Chem Biol       Date:  2018-06-11       Impact factor: 15.040

10.  Developing degraders: principles and perspectives on design and chemical space.

Authors:  Hannah J Maple; Nat Clayden; Anne Baron; Callum Stacey; Robert Felix
Journal:  Medchemcomm       Date:  2019-08-12       Impact factor: 3.597

View more
  17 in total

Review 1.  The PROTACtable genome.

Authors:  Melanie Schneider; Chris J Radoux; Andrew Hercules; David Ochoa; Ian Dunham; Lykourgos-Panagiotis Zalmas; Gerhard Hessler; Sven Ruf; Veerabahu Shanmugasundaram; Michael M Hann; Pam J Thomas; Markus A Queisser; Andrew B Benowitz; Kris Brown; Andrew R Leach
Journal:  Nat Rev Drug Discov       Date:  2021-07-20       Impact factor: 84.694

Review 2.  Cereblon: promise and challenges for combating human diseases.

Authors:  Hyoung Kyu Kim; Jung Eun Seol; Sang Woo Ahn; Seungje Jeon; Chul-Seung Park; Jin Han
Journal:  Pflugers Arch       Date:  2021-09-22       Impact factor: 3.657

Review 3.  The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.

Authors:  Liuxun Li; Jiangli Xu
Journal:  Clin Transl Oncol       Date:  2022-10-06       Impact factor: 3.340

Review 4.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 5.  Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.

Authors:  Chao Wang; Yujing Zhang; Lingyu Shi; Shanbo Yang; Jing Chang; Yingjie Zhong; Qian Li; Dongming Xing
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 6.  Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.

Authors:  Ruth Nussinov; Mingzhen Zhang; Ryan Maloney; Yonglan Liu; Chung-Jung Tsai; Hyunbum Jang
Journal:  J Mol Biol       Date:  2022-04-01       Impact factor: 6.151

7.  PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery.

Authors:  Giuseppe Ermondi; Diego Garcia-Jimenez; Giulia Caron
Journal:  Molecules       Date:  2021-01-28       Impact factor: 4.411

8.  The 2021 Nucleic Acids Research database issue and the online molecular biology database collection.

Authors:  Daniel J Rigden; Xosé M Fernández
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

Review 9.  E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points.

Authors:  Aleša Bricelj; Christian Steinebach; Robert Kuchta; Michael Gütschow; Izidor Sosič
Journal:  Front Chem       Date:  2021-07-05       Impact factor: 5.221

Review 10.  PROTAC targeted protein degraders: the past is prologue.

Authors:  Miklós Békés; David R Langley; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2022-01-18       Impact factor: 112.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.